147 related articles for article (PubMed ID: 36144563)
21. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.
Ugur O; Kostakoglu L; Hui ET; Fisher DR; Garmestani K; Gansow OA; Cheung NK; Larson SM
Nucl Med Biol; 1996 Jan; 23(1):1-8. PubMed ID: 9004907
[TBL] [Abstract][Full Text] [Related]
22. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
23. A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in Rats.
Zaid NRR; Kletting P; Winter G; Beer AJ; Glatting G
Cancer Biother Radiopharm; 2022 Feb; 37(1):41-46. PubMed ID: 34185608
[No Abstract] [Full Text] [Related]
24. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
25. Human dosimetry of free
Ukon N; Zhao S; Washiyama K; Oriuchi N; Tan C; Shimoyama S; Aoki M; Kubo H; Takahashi K; Ito H
EJNMMI Phys; 2020 Sep; 7(1):58. PubMed ID: 32960387
[TBL] [Abstract][Full Text] [Related]
26. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
[TBL] [Abstract][Full Text] [Related]
27. [Estimation of radiation dose produced by impurities in nuclear medicine studies using Tl-201 chloride].
Bergamini C; Marengo M; Laudicina L; Mazzotti G; Dondi M
Radiol Med; 1986 Sep; 72(9):656-9. PubMed ID: 3763969
[TBL] [Abstract][Full Text] [Related]
28. PET of malignant melanoma using 18F-labeled metallopeptides.
Ren G; Liu Z; Miao Z; Liu H; Subbarayan M; Chin FT; Zhang L; Gambhir SS; Cheng Z
J Nucl Med; 2009 Nov; 50(11):1865-72. PubMed ID: 19837749
[TBL] [Abstract][Full Text] [Related]
29. 201Tl-labelled TlCl dosimetry revisited.
Castronovo FP
Nucl Med Commun; 1993 Feb; 14(2):104-7. PubMed ID: 8429986
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution study of
Sakmár M; Kozempel J; Kučka J; Janská T; Štíbr M; Vlk M; Šefc L
Nucl Med Biol; 2024; 130-131():108890. PubMed ID: 38402673
[TBL] [Abstract][Full Text] [Related]
31. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.
Rbah-Vidal L; Vidal A; Billaud EM; Besse S; Ranchon-Cole I; Mishellany F; Perrot Y; Maigne L; Moins N; Guerquin-Kern JL; Degoul F; Chezal JM; Auzeloux P; Miot-Noirault E
Neoplasia; 2017 Jan; 19(1):17-27. PubMed ID: 27987437
[TBL] [Abstract][Full Text] [Related]
32. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog.
Cheng Z; Zhang L; Graves E; Xiong Z; Dandekar M; Chen X; Gambhir SS
J Nucl Med; 2007 Jun; 48(6):987-94. PubMed ID: 17504880
[TBL] [Abstract][Full Text] [Related]
33. Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies.
Matesan M; Fisher DR; Wong R; Gopal AK; Green DJ; Sandmaier BM; Bensinger W; Pagel JM; Orozco J; Press OW; Cassaday RD; Hutchinson E; Wanner M; Pal S; Thostenson C; Rajendran JG
J Nucl Med; 2020 Sep; 61(9):1300-1306. PubMed ID: 32169919
[TBL] [Abstract][Full Text] [Related]
34. Melanoma Imaging Using
Zhang C; Zhang Z; Lin KS; Lau J; Zeisler J; Colpo N; Perrin DM; Bénard F
Mol Pharm; 2018 Jun; 15(6):2116-2122. PubMed ID: 29714486
[TBL] [Abstract][Full Text] [Related]
35. Radiofluorinated rhenium cyclized α-MSH analogues for PET imaging of melanocortin receptor 1.
Ren G; Liu S; Liu H; Miao Z; Cheng Z
Bioconjug Chem; 2010 Dec; 21(12):2355-60. PubMed ID: 21073170
[TBL] [Abstract][Full Text] [Related]
36. Melanoma therapy via peptide-targeted {alpha}-radiation.
Miao Y; Hylarides M; Fisher DR; Shelton T; Moore H; Wester DW; Fritzberg AR; Winkelmann CT; Hoffman T; Quinn TP
Clin Cancer Res; 2005 Aug; 11(15):5616-21. PubMed ID: 16061880
[TBL] [Abstract][Full Text] [Related]
37. Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy.
Bordes J; Incerti S; Mora-Ramirez E; Tranel J; Rossi C; Bezombes C; Bordenave J; Bardiès M; Brown R; Bordage MC
Med Phys; 2020 Oct; 47(10):5222-5234. PubMed ID: 32623743
[TBL] [Abstract][Full Text] [Related]
38. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET.
Laforest R; Dehdashti F; Lewis JS; Schwarz SW
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):764-70. PubMed ID: 15785955
[TBL] [Abstract][Full Text] [Related]
39. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
40. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
